StockData

Abbott Laboratories vs Viatris

ABT and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABT and VTRS compare

Abbott Laboratories is the larger company, worth 7.8 times as much as Viatris ($186B against $23.8B).

Abbott Laboratories grew revenue faster over the last twelve months (8.1% versus 4.4% for Viatris).

Both pay dividends: Abbott Laboratories yields 2.3% and Viatris 2.3%.

Abbott Laboratories scores higher on the StockData Score (14 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABTVTRS
Size and price
Market cap$186B$23.8B
Share price$107.45$20.74
Change, 1 year−16.9%90.1%
Change, 5 years−14.6%62.7%
Beta (5Y)−0.490.32
Employees115K30K
StockData Score
Total score14 (better)6
Valuation score12 (better)
Growth score3 (better)1
Performance score3 (better)0
Health score4 (better)1
Dividend score3 (better)2
Valuation
P/E34.5×–
P/S4.0×1.6× (better)
P/B3.6×–
EV/EBITDA29.1×13.4× (better)
P/FCF23.8×12.2× (better)
FCF yield4.2%8.2% (better)
Fair value$78.34$22.57
Margin of safety−37.2%8.1% (better)
Growth
Revenue growth (TTM)8.1% (better)4.4%
Revenue growth, 5Y average5.1% (better)3.7%
Net income growth (TTM)−61.2%–
EPS growth (TTM)−61.1%–
EPS growth, 5Y average8.3%–
Profitability
Gross margin56.6% (better)34.8%
Operating margin15.8% (better)−0.59%
Net margin11.6%–
FCF margin16.8% (better)13.3%
Return on equity10.7%–
Return on invested capital7.9%–
Financial health
Debt / equity0.64–
Net debt / EBITDA3.68 (better)4.59
Interest coverage9.6× (better)−0.2×
Current ratio1.381.58 (better)
Altman Z-score3.30 (better)1.21
Piotroski F-score6–
Dividends and buybacks
Dividend yield2.3% (better)2.3%
Payout ratio78.5%–
Years of dividend growth3 (better)0
Buyback yield0.99%1.3% (better)
Shareholder yield3.3%3.6% (better)
Ownership
Held by institutions79.8%91.5%
Held by insiders0.50%0.36%
Insider net buying, 12 months−$43.3M−$1.1M (better)
Superinvestors holding23 (better)
Short interest, % of float1.1%3.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.